Meeting
2017 Gastrointestinal Cancers Symposium
Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers.
Authors
Diana Felice Hausman
Zymeworks Biopharmaceuticals, Seattle, WA
Diana Felice Hausman , Erika Paige Hamilton , Muralidhar Beeram , Jamuna Thimmarayappa , Gordon Ng , Funda Meric-Bernstam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Clinical Trial Registration Number
NCT02892123
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract TPS215)
DOI
10.1200/JCO.2017.35.4_suppl.TPS215
Abstract #
TPS215
Poster Bd #
N19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.
First Author: Qiao Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price
Poster
2022 ASCO Annual Meeting
Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
First Author: Ian E. Krop